Collaborative Drug Discovery (CDD) Vault: Company Profile

Background

Overview

Collaborative Drug Discovery (CDD) is a software company founded in 2004 by Dr. Barry A. Bunin as a spin-out from Eli Lilly & Co. The company specializes in providing informatics solutions for drug discovery, focusing on the management and analysis of chemical and biological data. Its flagship product, CDD Vault, is a web-based platform designed to streamline data management and foster collaboration among researchers in the pharmaceutical and biotechnology sectors.

Mission and Vision

CDD's mission is to offer an unparalleled software experience for both humanitarian and commercial collaborative research and discovery. The company aims to achieve this by focusing on its people, values, goals, innovation, and technology. A core aspect of CDD's vision is to enhance the efficiency and effectiveness of drug discovery processes through innovative informatics solutions.

Primary Area of Focus

CDD's primary focus is on developing and providing informatics platforms that support the management, analysis, and sharing of chemical and biological data in drug discovery. By offering tools that facilitate collaboration and data integration, CDD aims to accelerate the discovery of new therapeutics.

Industry Significance

In the pharmaceutical and biotechnology industries, efficient data management and collaboration are critical for the successful development of new drugs. CDD Vault addresses these needs by providing a secure and user-friendly platform that enables researchers to manage complex datasets, collaborate across teams, and make informed decisions, thereby contributing to the advancement of drug discovery.

Key Strategic Focus

Core Objectives

• Data Management: Develop and maintain a secure, scalable platform for managing chemical and biological data.

• Collaboration Enhancement: Facilitate seamless collaboration among research teams by providing tools that support data sharing and communication.

• Innovation in Informatics: Continuously innovate to incorporate advanced technologies, such as artificial intelligence, to enhance data analysis capabilities.

Specific Areas of Specialization

• Chemical Registration: Tools for registering and organizing chemical compounds.

• Assay Data Management: Modules for managing and analyzing biological assay data.

• Visualization Tools: Features that allow for the visualization of complex datasets to identify patterns and insights.

• Electronic Lab Notebook (ELN): A digital platform for recording and managing experimental data.

• Inventory Management: Systems for tracking the supply and location of compounds and reagents.

• Artificial Intelligence Integration: Incorporation of AI capabilities for tasks such as compound similarity searches and bioisosteric suggestions.

Key Technologies Utilized

• Cloud Computing: Ensures scalability and accessibility of the platform.

• Artificial Intelligence: Enhances data analysis and decision-making processes.

• Secure Data Storage: Protects intellectual property and sensitive research data.

Primary Markets Targeted

• Pharmaceutical Companies: To manage and analyze drug discovery data.

• Biotechnology Firms: For collaborative research and development.

• Academic Institutions: To support educational and research activities.

• Contract Research Organizations (CROs): For efficient data management in outsourced research projects.

• Agrochemical and Consumer Goods Companies: To manage chemical and biological data related to product development.

Financials and Funding

Funding History

CDD has raised a total of $4.52 million in funding over multiple rounds. The most recent funding round occurred two years ago, raising $300,000.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Utilization of Capital

The funds raised have been utilized to develop and enhance the CDD Vault platform, expand the company's product offerings, and support operational growth.

Pipeline Development

As a software company, CDD does not have a traditional pharmaceutical pipeline. Instead, the company focuses on the continuous development and enhancement of its informatics platform, CDD Vault, to meet the evolving needs of the drug discovery community.

Technological Platform and Innovation

Proprietary Technologies

• CDD Vault: A secure, web-based platform for managing chemical and biological data, facilitating collaboration among research teams.

Significant Scientific Methods

• Data Integration: Combines diverse datasets into a unified platform to streamline research workflows.

• Advanced Analytics: Utilizes built-in tools for data analysis, including curve fitting and statistical analysis.

• Artificial Intelligence: Incorporates AI capabilities for tasks such as compound similarity searches and bioisosteric suggestions.

AI-Driven Capabilities

• Generative Chemistry: Employs AI to suggest novel compounds with desired properties.

• Predictive Modeling: Uses machine learning algorithms to predict compound activity and toxicity.

Leadership Team

Barry A. Bunin, Ph.D. – CEO and Board Director

Dr. Bunin has overseen over $30 million in business transactions. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma.

Jeff Blaney, Ph.D. – Director of Computational Chemistry & Cheminformatics at Genentech

Dr. Blaney has many years of experience in industrial drug discovery research, focusing on structure-based design, high-throughput docking, combinatorial library design, and chemical informatics.

Henry W. B. Johnson, Ph.D. – Director at Kezar Life Sciences

Dr. Johnson was previously a senior member of the medicinal chemistry team at Onyx Pharmaceuticals, Inc., a subsidiary of Amgen. He has contributed to several drug discovery programs and was a primary contributor in the development of four small molecules which entered the clinic.

Thale Jarvis, Ph.D. – Chief Scientific Officer at Keystone Symposia

Dr. Jarvis has over 20 years of experience in biopharmaceutical drug discovery and development, serving as Principal Investigator on several grants supporting preclinical drug discovery at Crestone, and as scientific liaison with NIAID for Phase I clinical studies of CRS3123 for treatment of Clostridium difficile infections.

Daniel A. Erlanson, Ph.D. – VP of Chemistry at Frontier Medicines

Dr. Erlanson was the co-founder and President of Carmot Therapeutics, Inc., addressing unmet chemical needs in drug discovery to tackle challenging therapeutic targets. He has been an advisor to the SPARK Translational Research Program at Stanford University and edits a blog devoted to fragment-based drug discovery, Practical Fragments.

Competitor Profile

Market Insights and Dynamics

The market for drug discovery informatics platforms is growing, driven by the increasing complexity of drug discovery processes and the need for efficient data management and collaboration tools. Organizations are seeking solutions that can integrate diverse datasets, support collaboration across teams, and incorporate advanced analytics and AI capabilities.

Competitor Analysis

• InCrowd: Focuses on providing real-time market research solutions, with an estimated annual revenue of $12.9 million and 83 employees.

• DrugPatentWatch: Specializes in pharmaceutical patent intelligence, with an estimated annual revenue of $1.6 million and 8 employees.

• Atomwise: Utilizes AI for drug discovery, with an estimated annual revenue of $16.5 million and 82 employees.

• DrugDev: Offers clinical trial management solutions, with an estimated annual revenue of $158.4 million and 788 employees.

Strategic Collaborations and Partnerships

CDD has established significant collaborations, including a grant from the Bill & Melinda Gates Foundation in 2008 to support tuberculosis drug discovery, and adoption by the NIH for the Neuroscience Blueprint Network in 2012.

Operational Insights

CDD differentiates itself by offering a user-friendly, secure, and scalable platform that integrates various data management and analysis tools, facilitating collaboration among research teams and accelerating the drug discovery process.

Strategic Opportunities and Future Directions

CDD continues to innovate by incorporating advanced technologies such as artificial intelligence and machine learning into its platform, aiming to enhance data analysis capabilities and support the evolving needs of the drug discovery community.